Alpenglow Biosciences Expands Advisory Board with Two Esteemed Industry Leaders
Alpenglow Biosciences Expands Advisory Board with Two Esteemed Industry Leaders
Seattle, WA – April 3, 2025 – Alpenglow Biosciences, a leader in advanced digital pathology and 3D imaging, is excited to announce the appointment of Blandine Merino, M.S., and Mike Rice to its Advisory Board, joining Jesse Salk, M.D., Ph.D. Their combined expertise in next-generation sequencing (NGS), digital pathology, AI-driven cancer detection, and life science tools will play a key role in advancing Alpenglow’s innovation and growth in precision medicine.
Blandine Merino
Blandine Merino has over 20 years of experience in product development, business strategy, and operations across top companies like Guardant Health, Freenome, and Agilent. She has led major initiatives in NGS testing and AI-powered cancer detection, expanding partnerships with biopharma and academic centers. At Agilent, she pioneered a digital pathology strategy for companion diagnostics, integrating AI and advanced imaging.
Mike Rice
Mike Rice, former Chairman and CEO of BioLife Solutions, brings more than 17 years of leadership in life sciences tools. Under his guidance, BioLife grew significantly, increasing revenue from under $1 million to nearly $150 million. His expertise in scaling businesses, strategic acquisitions, and biopreservation technologies will help guide Alpenglow as it continues to innovate in pathology and 3D imaging solutions.
“We are thrilled to welcome Blandine and Mike to our Advisory Board,” said Nick Reder, MD, MPH, CEO and founder of Alpenglow Biosciences. “Their deep industry insights and proven leadership will be invaluable as we accelerate our efforts to transform pathology and precision medicine.”
Alpenglow’s proprietary platform enables whole tissue imaging in three dimensions, providing groundbreaking clarity for clinical diagnostics and research. With the addition of these industry leaders, the company is poised to drive the next phase of innovation in digital pathology.
Thank you and welcome, Blandine and Mike!
